U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Platinum-Resistant Primary Peritoneal Carcinoma

MedGen UID:
1676510
•Concept ID:
C4763750
•
Neoplastic Process
Synonym: Platinum-Resistant Primary Peritoneal Cancer

Definition

Primary peritoneal carcinoma that progresses between one and six months of completing the last platinum therapy. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPlatinum-Resistant Primary Peritoneal Carcinoma

Professional guidelines

PubMed

Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients.
Zhang N, Zheng H, Gao Y, Shu T, Wang H
BMC Womens Health 2023 Apr 13;23(1):178. doi: 10.1186/s12905-023-02329-9. PMID: 37055754Free PMC Article
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A, Kalachand R, Busschots S, Doherty B, Kapros E, Lawlor D, Hall N, Stordal BK
Cochrane Database Syst Rev 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3. PMID: 35866378Free PMC Article
Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.
Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA
Int J Gynecol Cancer 2018 May;28(4):738-748. doi: 10.1097/IGC.0000000000001222. PMID: 29538247

Recent clinical studies

Etiology

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ
Int J Gynecol Cancer 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924. PMID: 38101816
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW
Int J Gynecol Cancer 2023 Sep 4;33(9):1458-1463. doi: 10.1136/ijgc-2023-004812. PMID: 37666539
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W, Ricks TK, Pragani R, Arudchandran A, Patel P, Zaman S, Roy A, Kalavar S, Ghosh S, Pierce WF, Rahman NA, Tang S, Mixter BD, Kluetz PG, Pazdur R, Amiri-Kordestani L
Clin Cancer Res 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991. PMID: 37212825Free PMC Article
Bevacizumab in recurrent ovarian cancer.
Sait Bakir M, Birge O, Karadag C, Ilhan Y, Aykut Tuncer H, Sezgin Göksu S, Simsek T
J BUON 2021 Jul-Aug;26(4):1271-1278. PMID: 34564981
Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma.
Rose PG
Int J Gynecol Cancer 2005 May-Jun;15 Suppl 1:18-22. doi: 10.1111/j.1525-1438.2005.15357.x. PMID: 15839954

Diagnosis

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ
Int J Gynecol Cancer 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924. PMID: 38101816
Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas.
Arias-Diaz AE, Ferreiro-Pantin M, Barbazan J, Perez-Beliz E, Ruiz-Bañobre J, Casas-Arozamena C, Muinelo-Romay L, Lopez-Lopez R, Vilar A, Curiel T, Abal M
Int J Mol Sci 2023 Aug 25;24(17) doi: 10.3390/ijms241713208. PMID: 37686015Free PMC Article
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W, Ricks TK, Pragani R, Arudchandran A, Patel P, Zaman S, Roy A, Kalavar S, Ghosh S, Pierce WF, Rahman NA, Tang S, Mixter BD, Kluetz PG, Pazdur R, Amiri-Kordestani L
Clin Cancer Res 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991. PMID: 37212825Free PMC Article
Bevacizumab in recurrent ovarian cancer.
Sait Bakir M, Birge O, Karadag C, Ilhan Y, Aykut Tuncer H, Sezgin Göksu S, Simsek T
J BUON 2021 Jul-Aug;26(4):1271-1278. PMID: 34564981
Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma.
Rose PG
Int J Gynecol Cancer 2005 May-Jun;15 Suppl 1:18-22. doi: 10.1111/j.1525-1438.2005.15357.x. PMID: 15839954

Therapy

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ
Int J Gynecol Cancer 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924. PMID: 38101816
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
Colombo N, Van Gorp T, Matulonis UA, Oaknin A, Grisham RN, Fleming GF, Olawaiye AB, Nguyen DD, Greenstein AE, Custodio JM, Pashova HI, Tudor IC, Lorusso D
J Clin Oncol 2023 Oct 20;41(30):4779-4789. Epub 2023 Jun 26 doi: 10.1200/JCO.22.02624. PMID: 37364223Free PMC Article
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W, Ricks TK, Pragani R, Arudchandran A, Patel P, Zaman S, Roy A, Kalavar S, Ghosh S, Pierce WF, Rahman NA, Tang S, Mixter BD, Kluetz PG, Pazdur R, Amiri-Kordestani L
Clin Cancer Res 2023 Oct 2;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991. PMID: 37212825Free PMC Article
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, Provencher D, Memarzadeh S, Method M, Wang J, Moore KN, O'Malley DM
Gynecol Oncol 2023 Mar;170:241-247. Epub 2023 Feb 1 doi: 10.1016/j.ygyno.2023.01.020. PMID: 36736157
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN
Gynecol Oncol 2020 May;157(2):379-385. Epub 2020 Feb 18 doi: 10.1016/j.ygyno.2020.01.037. PMID: 32081463

Prognosis

Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas.
Arias-Diaz AE, Ferreiro-Pantin M, Barbazan J, Perez-Beliz E, Ruiz-Bañobre J, Casas-Arozamena C, Muinelo-Romay L, Lopez-Lopez R, Vilar A, Curiel T, Abal M
Int J Mol Sci 2023 Aug 25;24(17) doi: 10.3390/ijms241713208. PMID: 37686015Free PMC Article
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Banerjee S, Giannone G, Clamp AR, Ennis DP, Glasspool RM, Herbertson R, Krell J, Riisnaes R, Mirza HB, Cheng Z, McDermott J, Green C, Kristeleit RS, George A, Gourley C, Lewsley LA, Rai D, Banerji U, Hinsley S, McNeish IA
JAMA Oncol 2023 May 1;9(5):675-682. doi: 10.1001/jamaoncol.2022.7966. PMID: 36928279Free PMC Article
Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
Tatsuki S, Shoji T, Abe M, Tomabechi H, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Aida T, Baba T
Anticancer Res 2022 Sep;42(9):4603-4610. doi: 10.21873/anticanres.15964. PMID: 36039449
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD
Br J Cancer 2022 Jun;126(12):1695-1703. Epub 2022 Feb 11 doi: 10.1038/s41416-022-01717-6. PMID: 35149854Free PMC Article
Bevacizumab in recurrent ovarian cancer.
Sait Bakir M, Birge O, Karadag C, Ilhan Y, Aykut Tuncer H, Sezgin Göksu S, Simsek T
J BUON 2021 Jul-Aug;26(4):1271-1278. PMID: 34564981

Clinical prediction guides

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, Provencher D, Memarzadeh S, Method M, Wang J, Moore KN, O'Malley DM
Gynecol Oncol 2023 Mar;170:241-247. Epub 2023 Feb 1 doi: 10.1016/j.ygyno.2023.01.020. PMID: 36736157
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD
Br J Cancer 2022 Jun;126(12):1695-1703. Epub 2022 Feb 11 doi: 10.1038/s41416-022-01717-6. PMID: 35149854Free PMC Article
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer.
Yuan Z, Zhang Y, Cao D, Shen K, Li Q, Zhang G, Wu X, Cui M, Yue Y, Cheng W, Wang L, Qu P, Tao G, Hou J, Sun L, Meng Y, Li G, Li C, Shi H, Chen Y
J Ovarian Res 2021 Jan 11;14(1):12. doi: 10.1186/s13048-020-00736-2. PMID: 33423683Free PMC Article
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN
Gynecol Oncol 2020 May;157(2):379-385. Epub 2020 Feb 18 doi: 10.1016/j.ygyno.2020.01.037. PMID: 32081463
A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC, Lele S, Richard S, Secord AA, Leath CA 3rd, Brower SL, Tian C, Moore RG
Am J Obstet Gynecol 2014 Jul;211(1):68.e1-8. Epub 2014 Feb 12 doi: 10.1016/j.ajog.2014.02.009. PMID: 24530815

Recent systematic reviews

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A, Kalachand R, Busschots S, Doherty B, Kapros E, Lawlor D, Hall N, Stordal BK
Cochrane Database Syst Rev 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3. PMID: 35866378Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...